Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin. Issue 37 (September 2016)

• Record Type: Journal Article
• Authors: Wu, Hai Wei; Wang, Xuan; Zheng, Jia Wei; Zhao, Hai Guang; Ge, Jing; Zhang, Ling; Wang, Yan An; Su, Li Xin; Fan, Xin Dong
• Other Names: Liu. Yong section editor.
• Is Part Of: Medicine. Volume 95:Issue 37(2016)
• Publication Date: 2016-09
• Subjects: intralesional injection -- lymphatic malformations -- microcystic -- pingyangmycin; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000004790
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Treatment of microcystic lymphatic malformations (LMs) is still a great challenge to physicians in the field of managing vascular anomalies. Several kinds of treatment have been proposed for microcystic LMs, but the responses to these treatment modalities vary considerably among individuals. The aim of the study was to investigate the safety and efficacy of intralesional injection of pingyangmycin for microcystic LMs located in the deep facial region. Twenty-one consecutive patients with deep-seated facial microcystic LMs were treated with intralesional injection of pingyangmycin between March 2010 and April 2015. The patients received 2 to 8 injections, and the average session was 3.7. The therapeutic efficacy was accessed on the basis of the imaging findings and clinical measurements. Among the 21 patients, the clinical responses were excellent in 7 patients (33.33%), good in 9 patients (42.86%), fair in 3 patients (14.29%), and poor in 2 patients (9.52%). No severe side effects were encountered. Furthermore, therapeutic outcomes were significantly associated with lesion location ( P = 0.006) and number of injections ( P = 0.003). Our study supports that sclerotherapy with pingyangmycin is safe and effective for the treatment of deep-seated facial microcystic LMs.